TAO Hai-lin, LI Xin-yi, XIE Jun-kai, LI Yong-tao. Advances in antagonists and PROTAC of the nuclear receptor PXRJ. Acta Pharmaceutica Sinica, 2025, 60(12): 3605-3621. DOI: 10.16438/j.0513-4870.2025-1040
Citation: TAO Hai-lin, LI Xin-yi, XIE Jun-kai, LI Yong-tao. Advances in antagonists and PROTAC of the nuclear receptor PXRJ. Acta Pharmaceutica Sinica, 2025, 60(12): 3605-3621. DOI: 10.16438/j.0513-4870.2025-1040

Advances in antagonists and PROTAC of the nuclear receptor PXR

  • The pregnane X receptor (PXR) is a crucial member of the nuclear receptor superfamily and plays a pivotal role in regulating various biological processes. In recent years, significant progress has been made in the development of PXR antagonists and PXR-targeting proteolysis-targeting chimera (PROTAC). This review systematically summarizes recent advances in the study of PXR antagonists and PXR PROTAC drugs, with the aim of providing valuable insights and references for novel drug development and the exploration of new therapeutic targets in related fields.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return